Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
26 results
D1.402 - Study of lymphocyte populations and subpopulations in patients with long-COVID with reactivation of herpesvirus type 6 infection
D1.397 - Eosinophilic Pneumonia Triggered by Toxocara canis in a Patient with Kartagener Syndrome: A Case Report Highlighting Diagnostic Challenges and Interdisciplinary Management
D1.398 - Retrospective study of the effect of bacterial immunotheraphy on patients with chronic respiratory diseases
D1.403 - Use of ketotifen as treatment for post viral infection cough in children
D1.404 - Use of inactivated polybacterial mucosal vaccine (IPMV) as part of the treatment for the reduction of recurrent acute respiratory infections
D1.405 - Immunological imprinting of IgG response to RV VP1 in children of the MAS and PAPS birth cohorts
D1.406 - The microbiota of the urogenital canal related to papillomavirus infection
- D1.323 - Clinical Experience with Lanadelumab for Hereditary Angioedema in Kazakhstan
D3.317 - Moderate-to-severe infections and initial SELENA-SLEDAI correlate with the incidence of flares in patients with Systemic Lupus Erythematosus
D3.322 - Acquired chronic granulomatous disease secondary to myelodysplastic disorder
D3.324 - Mastoiditis as complication of Hyper IgM syndrome
D3.326 - A RARE COEXISTENCE: CARD9 DEFICIENCY AND IgG4-RELATED DISEASE IN A PEDIATRIC PATIENT
D3.327 - Use of C1 Inhibitor Subcutaneously in the United Kingdom
D3.328 - Relapsing COVID-19 pneumonia and Helicobacter cineadi cellulitis in a patient with X-linked agammaglobulinemia
D3.332 - Determination of Reference Intervals for IgG, IgA, and IgM Levels by Age in Healthy Adults
D3.419 - Prevalence of physical urticaria hives in patients with systemic mastocytosis and their relation to disease course – preliminary data
D3.411 - Targeting MRGPRX2 for the Treatment of Mast Cell-Driven Diseases
D3.412 - MRGPRX2 Specific Activation Signature is Enriched in Atopic Dermatitis Lesions and Wheals from Chronic Spontaneous Urticaria Compared to Adjacent Healthy Skin
D3.413 - Development of the Mastocytosis Symptom Severity Daily Diary (MS2D2) for Non-Advanced Systemic Mastocytosis (NonAdvSM) Patients and Establishing Content Validity
D3.414 - The Phase 2/3 Study of Elenestinib, a Highly Potent and Selective Tyrosine Kinase Inhibitor, in Patients With Indolent Systemic Mastocytosis
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download